Luis Jodar, PhD

Chief Scientific Officer
Pfizer Vaccines

Disclosure(s): Pfizer Inc: Employment, Stocks/Bonds (Public Company)

Poster(s):

• (P-604) Preliminary real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related lower respiratory tract disease (LRTD) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC), November 2023-April 2024
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-2054) Effectiveness of a Single COVID-19 mRNA Vaccine Dose in Individuals Previously Infected with SARS-CoV-2: A Systematic Review
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT